IQ EQ FUND MANAGEMENT IRELAND Ltd Increases Holdings in CareDx, Inc (NASDAQ:CDNA)

IQ EQ FUND MANAGEMENT IRELAND Ltd boosted its position in CareDx, Inc (NASDAQ:CDNA) by 41.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 9,343 shares of the company’s stock after buying an additional 2,742 shares during the quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd’s holdings in CareDx were worth $200,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also bought and sold shares of the company. Quarry LP purchased a new stake in shares of CareDx in the 3rd quarter valued at $27,000. Plato Investment Management Ltd grew its stake in shares of CareDx by 34.1% during the fourth quarter. Plato Investment Management Ltd now owns 5,390 shares of the company’s stock valued at $116,000 after buying an additional 1,370 shares during the last quarter. KLP Kapitalforvaltning AS bought a new position in shares of CareDx during the fourth quarter valued at about $208,000. Inceptionr LLC purchased a new position in shares of CareDx in the fourth quarter worth about $240,000. Finally, Bradley & Co. Private Wealth Management LLC bought a new stake in shares of CareDx in the 4th quarter valued at about $269,000.

Analysts Set New Price Targets

Several equities analysts recently issued reports on CDNA shares. StockNews.com upgraded CareDx from a “hold” rating to a “buy” rating in a research report on Wednesday, February 26th. Stephens restated an “overweight” rating and issued a $40.00 target price on shares of CareDx in a report on Thursday, February 27th. HC Wainwright lowered their price target on shares of CareDx from $26.00 to $25.00 and set a “neutral” rating for the company in a report on Monday, March 3rd. Finally, Wells Fargo & Company raised shares of CareDx from an “underweight” rating to an “equal weight” rating and cut their price target for the stock from $28.00 to $24.00 in a report on Wednesday, January 15th. Three investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $31.83.

CareDx Stock Down 2.1 %

NASDAQ:CDNA opened at $17.96 on Friday. The firm’s fifty day simple moving average is $21.39 and its 200 day simple moving average is $23.67. The stock has a market cap of $995.45 million, a P/E ratio of -6.65 and a beta of 1.95. CareDx, Inc has a twelve month low of $7.42 and a twelve month high of $34.84.

CareDx (NASDAQ:CDNA) last announced its earnings results on Wednesday, February 26th. The company reported $1.51 earnings per share for the quarter, beating analysts’ consensus estimates of $0.05 by $1.46. CareDx had a negative net margin of 45.90% and a negative return on equity of 53.70%. The firm had revenue of $86.58 million for the quarter, compared to analyst estimates of $84.56 million. On average, analysts expect that CareDx, Inc will post -0.9 EPS for the current fiscal year.

CareDx Company Profile

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.